Core Pharmaceutical Business Grows at High Speed
Operating Profit Increases 55%

On 25th April 2013, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma , stock code: 600196-SH, 02196-HK), announced its first quarter results of 2013 ended 31 March 2013. Focusing on core pharmaceutical business development, the operating profit of Fosun Pharma increased by 55% compared with the same period last year. Revenue increased 24.93% over the same period last year. Meanwhile, operating cash flows maintained a good momentum with a surge of 559.72% over the same period last year.

Fosun Pharma adhered to its business philosophy of “Innovation for Good Health”, promoted the strategies of organic growth, external expansion and integrated development, focused on its core pharmaceutical business and continued to grow the healthcare services segment. In the future, the Company will continually focus on pharmaceutical industry, devote resources to support the well development of healthcare services business and focus on high-profit and high-growth business as well.

The company highly focused on the R&D of pharmaceutical products and kept on its investment, so as to improve the Company’s productivity and efficiency. In 2012, the Company has 11 formulation items and series with sales revenue over RMB100 million.

Mr. Chen Qiyu, Chairman of Fosun Pharma, said, “Fosun Pharma’s managements express full confidence in the future development of the Company. We will continue to improve the company’s management ability and operation quality, be committed to improve public health as our mission, strengthen development of product innovation and product marketing system, and enhance the core competence of the Company and further improve the profits. Meanwhile, we will further strengthen our efforts in acquiring quality companies in the pharmaceutical industry, optimize and integrate various resources in the pharmaceutical industry, bringing satisfactory returns to our shareholders.”